The aim is to design and optimize cyclic peptide ligands that specifically target DLL3.
Introduced a rigid cyclopropane mimic at a specific valine residue
Characterized the binding affinity using KD measurements
B5, a cyclic peptide ligand, showed high binding affinity for DLL3 with KD of 12.3 nM
This study identifies a promising DLL3-targeted theranostic scaffold
Abstract
Introducing a rigid cyclopropane mimic at a key valine residue yielded B5, a high-affinity cyclic peptide ( K D = 12.3 nM) targeting DLL3, providing a potential DLL3-targeted theranostic scaffold.